Anna Dostalova, Anneli Andersson, Jana Sponarova, and Philip Zimmermann
© NEBION AG. April 2019.
Immune-evading pathways are currently being clinically targeted, but the therapies are not effective in all patients and all cancer types. Therefore, more efficient approaches are needed to predict responsiveness and also to discover and characterize novel targets as alternative or combination treatments. In this study, we used GENEVESTIGATOR® for biomarker validation and characterization of a gene signature predictive of reponse to immunotherapy. GENEVESTIGATOR® is an analysis tool and database, containing high quality curated gene expression data. It allows the user to mine the data of thousands of experiments simultaneously, to identify genes having a very specific profile or indications associated with the transcriptional activity of selected genes.